US FDA approves Retevmo for lung, thyroid cancers with certain genetic mutations
It is the first therapy approved specifically for cancer patients with the RET gene alterations
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Loxo Oncology
Lilly’s targeted RET drug shrinks tumours in lung cancer trial
Lilly’s drug, now called selpercatinib, is intended for patients with rare RET abnormalities, which occur in about 2 per cent of…